Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Tilray Brands Inc (TLRY) vs GeneDx Holdings Corp (WGS) Price & Performance

Tilray Brands IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Tilray Brands Inc vs GeneDx Holdings Corp — how do they compare? Tilray Brands Inc trades at $4.75 (market cap $649.42M), while GeneDx Holdings Corp trades at $82.37 (market cap $2.44B). The key difference: GeneDx Holdings Corp is far larger — about 3.8× Tilray Brands Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

TLRYWGS
Market Cap
$649.42M$2.44B
Sector
HealthTechnology
52-Week High
$21.00$167.51
52-Week Low
$3.88$34.51
Enterprise Value
$816.55M$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Tilray Brands Inc

TLRY trades at $4.77, up 7.92% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record fiscal 2026 revenue of $915 million (GlobeNewsWire, July 28, 2026) but posted a net loss. Key financials show a low P/S of 0.58 and P/B of 0.4, yet profitability remains challenged with negative net income margins and ROE.

Outlook is cautiously optimistic due to revenue growth and diversification into beverages and wellness, but high execution risk persists from consistent losses and competitive pressures. Analyst sentiment is mixed with 25% buy ratings, suggesting potential upside if profitability improves, though near-term volatility is likely.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS